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Objectives: Accurate measurement of IgG subclass (IgGSc) levels are essential to aid in the diagnosis of dis-
ease states such as primary immunodeﬁciencies. However, there is no single standardisation of nephelometric
and turbidimetric assays for these analytes and two referencematerials have been utilised. We expand on previ-
ous reports and present data from a multi-site analysis that both identiﬁes and quantitatively deﬁnes the differ-
ences in calibration resulting from the use of different reference materials.
Design and methods: IgGSc antibodies in the serum specimens and reference materials were measured
according to the manufacturers' instructions using commercially available IgGSc assays or components.
Results: Data from four independent sites showed that in spite of the different commercial suppliers of IgGSc
assays calibrating to different reference materials, ERM-DA470k and WHO67 /97, the resulting calibrations were
comparable for IgG1 and IgG2. However, for IgG3 and IgG4 the calibrations were signiﬁcantly different. The use of
assay speciﬁc normal ranges should compensate for these calibration differences, however, the twomanufacturers'
assays can give differing clinical classiﬁcations. The agreement between the different manufacturers' IgGSc assays
was between 85.1% and 95.8% for all IgGSc assays, the discordance of sample classiﬁcation for IgG1 and IgG2 assays
was approximately 12% and 15% respectively, whilst that for IgG3 and IgG4 was 4% and 13% respectively.
Conclusion: We discuss the similarities and differences between assays that utilise the different reference
materials.© 2013 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc.
Open access under CC BY-NC-ND license. Introduction
The measurement of IgG subclasses (IgGSc) is performed as part of
an immune system evaluationwhere there is a continued clinical suspi-
cion of an IgGSc imbalance, particularly in the background of normal
total IgG levels. Deﬁciency in IgGSc levels has been found to be associat-
edwith a variety of immunodeﬁciency syndromes such as common var-
iable immunodeﬁciency, ataxia telangiectasia and IgA deﬁciency aswell
as upper respiratory tract infections such as severe swine ﬂu [1–6]. The
measurement of all four IgGSc forms part of the accepted protocol for
diagnosis of an IgG subclass deﬁciency. The concentration of IgGSc is
age dependant and normal IgGSc concentrations change signiﬁcantly
as the immune system matures. In neonates, placental transfer plays. Parker).
Clinical Chemists. Published by Elsevan important part in determining IgGSc levels and the majority of IgG
present at birth is derived fromplacental transfer from themother. Dur-
ing the ﬁrst 6 months of life levels decrease as the neonate develops the
synthetic mechanisms to produce their own IgG. IgG1 and IgG3 levels
increase most rapidly with near adult levels reached by the age of 12,
adult levels of IgG2 and IgG4 are reached muchmore slowly. These sig-
niﬁcant differences between the IgGSc concentrations in children and
adults have to be taken into account when interpreting IgGSc results.
Both paediatric and adult normal ranges have been established for the
IgGSc from the different commercial reagent suppliers to enable their
use in disease diagnosis [7,8].
The standardisation of normal ranges for the measurement of IgGSc
has proven difﬁcult for several reasons: (1) different methods have
been used for measurement, (2) study cohorts that have been used
may differ in age, race, sex and number of subjects and (3) the use of dif-
ferent statistical analyses for data interpretation. Standardisation has
been further hampered due to their being no single international refer-
ence material recognised for the determination for IgGSc. The three
commercial sources of IgGSc assays use two different calibrations: in
the case of The Binding Site (TBS) Certiﬁed Reference Material 470ier Inc. Open access under CC BY-NC-ND license. 
Table 1
Intra-assay precision and sample linearity of TBS and Siemens IgGSc assays.
For intra-assay precision: twenty seven replicateswere assayed for each sample in each of
the manufacturer's individual IgGSc assays and percent coefﬁcient of variation (%CV) was
calculated.
For linearity: the samples were diluted to 75%, 50% and 25% of its original concentration
and the values of the dilution recorded. The percentage deviation from the expected
value was determined as described in materials and methods. All individual dilutions
were assayed in triplicate.
Manufacturer Function IgG1 IgG2 IgG3 IgG4
TBS % CV 3.3 1.8 3.6 3.1
mg/L 7971.3 4542.6 650.4 426.2
Linearity:
% Deviation from
expected value
75% 4.1 −1.9 1.8 −3.7
50% −0.7 −2.7 2.8 −4.0
25% −1.1 −5.0 3.3 −7.0
Siemens % CV 1.6 1.9 5.0 2.9
mg/L 9364.9 4246.5 371.2 675.6
Linearity:
% Deviation from
expected value
75% −0.1 −0.1 −2.2 2
50% 8.6 −3.3 −7.1 5.7
25% 16.6 0.3 4.5 −0.7
1752 C. Wilson et al. / Clinical Biochemistry 46 (2013) 1751–1755(CRM470; now superseded with ERM-DA470k due to depletion of
CRM470 stocks [7]) [9] and in the case of Sanquin and Siemens
WHO67/97 [10] (later replaced by the commercial calibration material
Sanquin M1590).
Bossuyt et al. [11] have previously reported the differences in cali-
bration and thus data interpretation between TBS IgGSc assays and
the Sanquin IgGSc assays. A commentary has recently been published
highlighting the major difference between TBS and Siemens IgGSc
assay calibration and concluded that this difference was due to the as-
says being standardised against two different reference materials [12].
Here, we expand on previous reports and present data from a multi-
site analysis that both identiﬁes and quantitatively deﬁnes the differences
in calibration resulting from the use of different reference materials.
Furthermore, the subsequent effect this has on classiﬁcation of patient
samples is also presented.Manufa
Concentration (mg/L)
IgG1
Fig. 1. Box andWhisker plot showing the comparison between IgG subclass assays and different
IgG4 a signiﬁcant difference between themanufacturers' assays is observed. The assayswere run
in themiddle of the box represents themedian value of the combined data set from all study sit
value of the lower quartile. The high error bar represents the highest value and the low error bMaterials and methods
Assay method
IgGSc antibodies in the serum specimens and reference materials
were measured according to the manufacturers' instructions using
commercially available IgGSc assays: SPAPLUS IgGSc assays (IgG1–IgG4;
NK006.S, NK007.S, LK008.S, LK009.S; The Binding Site, UK). Siemens
BNII IgGSc assays were performed with the following components: N AS
IgG1 (OQXI092), N AS IgG2 (OQXK092), N Latex IgG3 (OPAV032), and
N Latex IgG4 (OPAU032), N-supplementary reagent (OQTD115), Siemens
Cleaner SCS (OQUB195), and the N protein standard SL (OQIM135)
(Siemens Healthcare Diagnostic Products, Germany).
The adult normal ranges stated for the TBS assays are IgG1: 3.82–
9.29 g/L, IgG2: 2.42–7.00 g/L, IgG3: 0.22–1.76 g/L, IgG4: 0.04–0.87 g/L
and for the Siemens assays IgG1: 4.1–10.1 g/L, IgG2: 1.7–7.9 g/L, IgG3:
0.11–0.85 g/L, IgG4: 0.03–2.0 g/L.
Precision
The precision of each assay was compared by running twenty seven
replicates of the same sample on each assay on both the Siemens BNII
and the TBS SPAPLUS IgGSc assays. The sample consisted of pooled
human serum with IgGSc levels within the standard measuring range
for each assay on both manufacturers' assays.
Linearity
A serum sample was identiﬁed that gave a readable concentration
towards the upper value of the measuring range for each IgGSc on
both manufacturer's assays. Dilutions of the samples were prepared
at 75%, 50% and 25% concentration of the original ﬂuid. The linearity
of the IgGSc assays was assessed by running each dilution in tripli-
cate and comparing the mean result to the expected results. Thecturer’s of IgG subclass assays
IgG2 IgG3 IgG4
IgG subclasses
manufacturers. There is a good agreement between the IgG1 and IgG2 assays. For IgG3 and
as described in themanufacturer's inserts and themethods andmaterials section. The line
es, the upper edge of the box represents the value of the upper quartile, the lower edge the
ar the lowest value in the sample population.
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concentration obtained at 100% (no dilution). The % deviation from
linearity was calculated as ((concentration obtained/concentration
expected)*100).Method comparison
Randomly selected human serum samples were collected at each of
the four independent sites andmeasured on each of the manufacturers'
IgGSc assays.Statistical analysis
Pearson correlation, Altman–Bland analysis, and Deming regression
analysis were all performed using Analyse-It software. Percent coefﬁ-
cient of variation was calculated in Excel using the following formula:
((Standard deviation/mean)*100).Table 2
IgG subclass comparison characteristics between TBS and Siemens IgGSc assays.
Human serumsampleswere assayed in all four subclass assays frombothmanufacturers at
four independent sites. The data were analysed to quantitatively measure the correlation
and agreement between the appropriate subclass assays.
Performed at TBS 
IgG1 (n=30) IgG2 (n=30) IgG3 (n=25) IgG4 (n = 30)
Pearson correlation 0.97 0.99 0.92 0.93
95% CI 0.94-0.99 0.98-1.00 0.83-0.96 0.82-0.97
Altman−Bland: bias -1699.3 537.9 588.2 -136.6
95% CI -1935.2 to - 
1463.5
444.80
to 631.1
463.9 to 
712.6
-257.4 to -
15.7
Deming regression: intercept 29.68 110.82 -121.4 104.88
95% CI -965.73 to 
1025.09
-75.7 to -
297.35
-351.05-
108.25
-102.01-
311.77
Deming regression: slope 0.81 1.13 2.16 0.63
95% CI 0.7-0.93 1.07-1.19 1.70-2.63 0.2-1.025
Performed at site A 
IgG1 (n=40) IgG2 (n=40) IgG3 (n=40) IgG4 (n = 41)
Pearson correlation 0.98 1.00 0.98 0.99
95% CI 0.96-0.99 0.99-1.00 0.96-0.99 0.97-0.99
Altman−Bland: bias -1221 16.73 366.7 -302.7
95% CI -1399 to -
1044
-81.96 to -
48.5
263.3 to 
470.1
-440.8 to -
164.6
Deming regression: intercept -360.0 30.0 -160.0 20.0
95% CI -760 to 50 50.0 to 110 -250 to -60.0 -10.0 to 60
Deming regression: slope 0.88 0.98 2.18 0.57
95% CI 0.82 to 0.93 0.95 to 1.02 1.94 to 2.41 0.53 to 0.61
Performed at site B
IgG1 (n=51) IgG2 (n=51) IgG3 (n=47) IgG4 (n = 40)
Pearson correlation 0.99 0.96 0.94 0.98
95% CI 0.99-1.00 0.93-0.98 0.89-0.97 0.96-0.99
Altman−Bland: bias -899.5 362.6 352.9 -511.1
95% CI -1097.0 to - 
701.9
194.1 to 
531.2
283.3 to 
422.4
-723.5 to -
298.6
Deming regression: intercept -680.0 250.0 -50.0 60.0
95% CI -1223 to -140 -400 to 890 -150.0 to 
50.0
20.0 to 110.0
Deming regression: slope 0.98 1.03 1.88 0.50
95% CI 0.91-1.04 0.8-1.3 1.57-2.19 0.43-0.56
Performed at site C
IgG2 (n=46) IgG3 (n=34) IgG4 (n = 33)
Pearson correlation 0.96 0.97 0.99
95% CI 0.93-0.99 0.93-0.98 0.97-0.99
Altman−Bland: bias 390.8 459.9 -292.1
95% CI 272.2 to 
509.4
-351.3 to 
568.3
-458.0 to -
126.1 
Deming regression: intercept 293.8 122.9 62.5
95% CI -132.6 to 
720.3
0.7 to 245.2 23.05 to 
101.96
Deming regression: slope 1.03 1.53 0.52
95% CI 0.87 to 1.18 1.35 to 1.71 0.46 to 0.57Results
Measurement of assay performance and assay comparison
Intra-assay precision and sample linearity were calculated for each
assay (Table 1) with one sample assayed per IgGSc. The intra-assay pre-
cision for all IgGSc assays were ≤5% with IgG3 subclass assays the least
precise for eachmanufacturer. The linearity study showed that deviation
from the expected values were b10% for all assays with the exception of
the sample diluted to 25% of its original concentration in the Siemens
IgG1 assay which showed a variation of 16.6% from the expected value.
Results from the comparison studies using both manufacturers' as-
says are shown in Fig. 1 and Table 2. The correlation between the IgG1
and IgG2 values were good (Deming regression slope IgG1; 0.81–0.98
and IgG2; 0.98–1.13). Correlation of IgG3 and IgG4 however suggested
signiﬁcant differences existed between the values obtained on the dif-
ferent manufacturers' assays (Deming regression slope IgG3; 1.53–
2.18 and IgG4; 0.50–0.63).
Quantitation of assay comparison
The values obtained for both the IgG1 and IgG2 in ERM-DA470k
were within 15% of each other when assayed with either TBS IgGSc or
Siemens IgGSc assays (Fig. 2). The difference between the values
obtained for IgG3 and IgG4 with the different manufacturers' assays,
however, was much greater and further supported the observation of
substantial calibration differences between the two manufacturers' as-
says. For IgG3 the percentage difference in values obtained was N40%
(304 mg/L in the Siemens assay vs. 559 mg/L in the TBS assay) and
N60% in the IgG4 assay (607 mg/L in the Siemens assay vs. 374 mg/L
in the TBS assay).
Effect of different calibrations on sample classiﬁcation
We investigated whether there were any differences in sample clas-
siﬁcation due to the calibration differences between the TBS andSiemens
IgGSc assays, particularly the IgG3 and IgG4, for a range of samples mea-
sured at the four sites (Table 3).
The overall agreement between the different IgGSc assays, that is the
percentage of samples that fell into the same classiﬁcation on both as-
says, was N85% in all four IgGSc assays (85.1%–95.8%). Even though
the linear regression analysis of the results from the IgG1 and IgG2 as-
says gave slopes suggesting reasonable agreement and certainly far
closer agreement than between the IgG3 and IgG4 assays, the discor-
dance of sample classiﬁcation for both the IgG1 and IgG2 assays wasConcentration (mg/L)
IgG1 IgG2 IgG3 IgG4
IgG subclasses
Manufacturer’s of IgG subclass assays
Fig. 2. Plot of mean values for ERM-DA470k standard obtained on TBS IgGSc assays and
Siemens IgGSc assays. There is a good agreement between the IgG1 and IgG2 assays. For
IgG3 and IgG4 a signiﬁcant difference between the manufacturers' assays is observed.
ERM-DA470k was diluted according to the manufacturer's instructions and run three
times in triplicate in all assays. The error bars represent three standard deviations.
Table 3
Sample classiﬁcation in the TBS and Siemens IgGSc assays.
Randomly selected human serum samples were run at four independent locations
(IgG1, n = 121; IgG2 n = 167; IgG3, n = 141; IgG4, n = 121) on all four IgGSc as-
says. The resulting sample values were classiﬁed using the normal ranges in each
manufacturer's insert. (1) low, below the stated normal range; (2) normal, within
the stated normal range and (3) high, higher than the stated normal range.
The % agreement between each subclass assay from the two manufacturer's was
calculated by dividing the number of samples that showed agreement in classiﬁcation
by the total number of samples assayed (shaded boxes).
Siemens
Binding site Low Normal High
Low IgG1 0% 
IgG2 3%
IgG3 2.1%
IgG4 0%
IgG1 4.1%
IgG2 10.1%
IgG3 0%
IgG4 0.8%
IgG1 8.3%
IgG2 0% 
IgG3 0.7% 
IgG4 0%
Normal IgG1 0% 
IgG2 0%
IgG3 0.7%
IgG4 7.6%
IgG1 69.4%
IgG2 65.9%
IgG3 83.8%
IgG4 73.9%
IgG1 0%
IgG2 0%
IgG3 0%
IgG4 0%
High IgG1 0%
IgG2 4.8% 
IgG3 2.8% 
IgG4 4.2% 
IgG1 0%
IgG2 0%
IgG3 0%
IgG4 0%
IgG1 18.2% 
IgG2 16.2% 
IgG3 9.9% 
IgG4 13.5% 
% agreement IgG1 87.6%
IgG2 85.1% 
IgG3 95.8% 
IgG4 87.4% 
Table 4
Publication search of IgGSc percentage composition in the absence of external reference
material.
Publications inwhich the relative levels of IgGSc have been investigated. Column1 lists the
references, column 2 states the subclass method used, column 3 states the sample types
and column 4 summarises the relative proportions of each IgGSc as a percentage.
Reference Method Sample
type
% Ratio IgG1:
IgG2:IgG3:IgG4
Van der Giessen,
1975 [15]
Radial immunodiffusion Normal samples 58:31.2:5.3:4.9
Skvaril, 1972 [17] Agar electrophoresis IgG myeloma 80:10:6.4:3.6
Skvaril, 1972 [17] Agar electrophoresis Normal samples 56:29:10.5:4.5
Morrell, 1972 [18] Radioimmunoassay Normal samples 60.9:29.6:5.3:4.2
Trebeden, 1997 [19] Immunoﬁxation IgG myeloma 74:11:11:4
Leddy, J 1970 [20] Radioimmunoassay Healthy 64:28:5:3
Morell, 1971 [14] Radioimmunoassay Normal myeloma 63:28:6:3
French 1984 [21] Radial immunodiffusion Normal healthy 60.3:31:6.2:2.5
Schur, 1970 [22] immunoelectrophoresis Normal healthy 70:23.7:3.7:2.6
Shakib, 1975, Schur,
1970 [22,23]
Radial immunodiffusion Normal healthy 71.5:19.4:8.4:0.7
1754 C. Wilson et al. / Clinical Biochemistry 46 (2013) 1751–1755approximately 12% and 15% respectively, whilst that for IgG3 and IgG4
was 4% and 13% respectively (Table 3).
Discussion
The accurate and reproducible measurement of IgGSc is essential to
aid the diagnosis of both hypo- and hyper-gammaglobulinaemias par-
ticularly in the presence of normal serum IgG levels. The concentration
of IgGSc can vary with age, gender, race, laboratory to laboratory due to
method differences as well as reference material and calibration differ-
ences. Bossuyt and colleagues previously noted that disparity exists be-
tween IgG3 and IgG4 assays calibrated with different materials [11].
They concluded that this was the direct result of standardising the as-
says with incongruent calibration referencematerials. Our recent publi-
cation highlighted the differences in the paediatric reference intervals
between both types of standardised assays and the use of different ref-
erence materials, WHO 67/97 and ERM-DA470k. We further concluded
that the appropriate reference intervals must be applied to the appro-
priate assay in accordance with the individual manufacturer's recom-
mendations [12].
Deming regression analysis and quantitation of ERM-DA470k have
suggested that although the calibrations were acceptable and compara-
ble between the IgG1 and IgG2 assays but not between the IgG3 and
IgG4 assays, all four paired IgGSc assays from the different manufac-
turers were statistically different. Calibration is not the only cause of
differences between the manufacturers' assays, the instrumentation
used or the antiserum may have an inﬂuence. We compared the Sie-
mens data with data obtained using the Sanquin IgGSc assays for the
IMMAGE, both assays utilise WHO67/97 as a reference material. Whilst
the data obtained for IgG3 and IgG4 were more comparable than found
in this study for the IgG2 assay some differences in measurement were
observed (Deming regression slope [95%CI]: IgG1, 0.93 [0.87–0.98];
IgG2, 0.78 [0.64–0.92]; IgG3, 0.94 [0.74–1.15] and IgG4, 1.25 [0.46–
2.05]) (unpublished data).
Measurement of the concentrations of IgGSc, in particular IgG3 and
IgG4, in WHO67/97 have shown considerable laboratory to laboratory
variability [10]. Using WHO67/97 as the calibrant or as the sample
there have been reports which suggest that concentration of IgG3 in
WHO67/97 was higher than that of IgG4 [13,14] but also reports
suggesting it was lower than IgG4 [10,13,15]. It is likely that the root
cause of much of the between laboratory variation and the calibration
differences of the IgG3 and IgG4 assays is the stability of these analytesin the early referencematerialWHO 67/97 and its suitability for nephe-
lometric or turbidimetric assays. Whicher reported the precipitation of
residual proteins from long term storage of WHO material [16] which
has been shown to decrease the precision of nephelometric and turbidi-
metric assays. Klein and colleagues reported that the levels of IgG3were
unstable inWHO67/97 andmay be the reason for the laboratory to lab-
oratory variation observed in the measurement of WHO 67/97 IgG3
concentrations obtained and the under reading of IgG3 levels [10].
It appears likely that the lower calibration of IgG3 adopted in the Sie-
mens assaymay be due to the degradation of IgG3 in the early reference
preparationWHO67/97 and this view is further supported by themany
publications that have investigated the levels of the IgGSc (Table 4).
With the exception of one study the results clearly indicatewith consid-
erable consistency that the concentration of IgG3 N IgG4 in human
serum. The relative concentrations of IgGSc in CRM470have been deter-
mined nephelometrically to be IgG1 N IgG2 N IgG3 N IgG4 [7] and are
in agreement with published literature in Table 4. CRM470 (replaced
by ERM-DA470k due to stock exhaustion) was accepted as the Interna-
tional Reference Preparation for proteins in human serum in 1992 and
the long term stability of the analytes including IgG has been shown.
However, although the IgG1 and IgG2 assays have similar calibra-
tions and give comparable values on patient samples, the normal ranges
given within the manufacturers' inserts differ signiﬁcantly. When these
are applied this leads to classiﬁcation discordance of up to 15% between
the patient samples assessed in this study and thus emphasises the re-
quirement to use manufacture speciﬁc normal ranges and the lack of
assay interchangability.
Standardisation of immunoassays is necessary to minimise inter-
laboratory variation and the implementation of CRM 470 for the major
serumassays illustrates how this approach can be successful. A common
reference material is required for standardisation and therefore ideally,
a single internationally accepted reference material should be adopted
for the IgGSc assays; in the absence of this an appropriate conversion
factor between the different materials may be beneﬁcial. However,
manufacturer normal ranges are suppliedwith each assaywhich should
in theory compensate for the impact of using different reference mate-
rials for their respective calibration. This was indeed the case for IgG3
and IgG4 in this study but there were surprisingly large differences
between sample classiﬁcations when measuring IgG1 and IgG2,
harmonisation of reference ranges would also be required to minimise
inter-laboratory differences.
In summarywe have provided detailed evidence that the calibration
of IgG1 and IgG2 Siemens and Binding Site assays are similar but that
the calibration of IgG3 and IgG4 assays are signiﬁcantly different and
we have provided a plausible explanation for this difference. For all
IgGSc assays the reference ranges quoted in the manufacturers' inserts
1755C. Wilson et al. / Clinical Biochemistry 46 (2013) 1751–1755are different and this leads to differences in sample classiﬁcation partic-
ularly for IgG1, IgG2 and IgG4 the assays and reference ranges should
not be used interchangeably.References
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